Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue $ 441 $ 0
Cost of goods sold 199 0
Gross profit 242 0
Research and development 5,602 18,136
General and administrative 27,853 40,954
Depreciation and amortization 198 94
Total operating expenses 33,653 59,184
Loss from operations (33,411) (59,184)
Other income (expense):    
Interest income, net 2 45
Gain on settlement of debt 553 0
Loss on foreign currency translation 0 (1)
Loss before income taxes (32,856) (59,140)
Income taxes (benefit) 0 0
Net loss (32,856) (59,140)
Non-controlling interest 939 6,922
Net loss attributable to BioSig Technologies, Inc. (31,917) (52,218)
Preferred stock dividend (9) (14)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (31,926) $ (52,232)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.95) $ (1.87)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 33,511,941 27,906,584
Product [Member]    
Revenue $ 414 $ 0
Service [Member]    
Revenue $ 27 $ 0